Mike Doustdar

Mike Doustdar is the new Chief Executive Officer of Novo Nordisk, a Danish pharmaceutical company known for producing drugs like Wegovy and Ozempic. He and Chairman Lars Rebien Sorensen are facing scrutiny from shareholders regarding the company's direction and performance. Doustdar's tenure begins amidst significant challenges, including a projected sharp drop in revenue for 2026. This decline is attributed to factors such as potential price reductions driven by political pressure (Donald Trump), increased competition in the weight-loss drug market, and the expiration of key patent protections. Despite these headwinds, Novo Nordisk recently achieved a milestone with the FDA approval of a pill form of Wegovy, offering a more convenient alternative to injectable versions. Doustdar's leadership will be crucial in navigating these complexities and shaping Novo Nordisk's future in a rapidly evolving pharmaceutical landscape.